Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy

Human cardiac 31P nuclear magnetic resonance (NMR) spectra are usually quantified in relative terms, i.e., the ratio of metabolite signals is calculated. If 31P NMR spectroscopy of the heart is to emerge as a clinically relevant diagnostic modality, reliable quantification of absolute concentrations of 31P metabolites is required. We applied spectral localization with optimal point spread function (SLOOP) 31P NMR spectroscopy to measure absolute concentrations of phosphocreatine (PCr) and adenosine triphosphate (ATP) in human myocardium. The accuracy of the quantification was first validated in a phantom study. Seven healthy volunteers (aged 19–29 years) were then examined at 1.5 T using a nominal spatial resolution of 25 mL. SLOOP allowed us to obtain localized spectra from compartments anatomically matched to the left ventricular wall. The a priori knowledge of the anatomical structure was obtained from 1H images. The spatially varying effects of saturation, off‐resonance, and sensitivity were considered during the reconstruction process. Metabolites were quantified with reference to an external 31P standard. Concentrations of 9.0 ± 1.2 and 5.3 ± 1.2 mmol/kg wet wt (mean ± SD, n = 9) were determined for PCr and ATP in normal heart, respectively. The influence of nuclear Overhauser enhancement on metabolite quantification is discussed. Magn Reson Med 41:657–663, 1999. © 1999 Wiley‐Liss, Inc.

[1]  C. Hardy,et al.  Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. , 1990, The New England journal of medicine.

[2]  O. Lutz,et al.  31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. , 1998, Circulation.

[3]  C J Hardy,et al.  Phosphate metabolite imaging and concentration measurements in human heart by nuclear magnetic resonance , 1990, Magnetic resonance in medicine.

[4]  C. Hardy,et al.  Proton overhauser enhancements in human cardiac phosphorus NMR spectroscopy at 1.5 T , 1992, Magnetic resonance in medicine.

[5]  D. van Ormondt,et al.  Analysis of NMR Data Using Time Domain Fitting Procedures , 1992 .

[6]  D. van Ormondt,et al.  SVD-based quantification of magnetic resonance signals , 1992 .

[7]  D. T. Pegg,et al.  Theoretical description of depth pulse sequences, on and off resonance, including improvements and extensions thereof , 1985, Magnetic resonance in medicine.

[8]  S. Neubauer,et al.  31P Magnetic Resonance Spectroscopy in Dilated Cardiomyopathy and Coronary Artery Disease: Altered Cardiac High‐Energy Phosphate Metabolism in Heart Failure , 1992, Circulation.

[9]  A. Staubert,et al.  Proton-decoupled myocardial 31P NMR spectroscopy reveals decreased PCr/Pi in patients with severe hypertrophic cardiomyopathy. , 1997, The American journal of cardiology.

[10]  C. Hardy,et al.  Correcting human heart 31P NMR spectra for partial saturation. Evidence that saturation factors for PCr/ATP are homogeneous in normal and disease states , 1991 .

[11]  K. Uğurbil,et al.  NMR chemical shift imaging in three dimensions. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Vanhamme,et al.  Improved method for accurate and efficient quantification of MRS data with use of prior knowledge , 1997, Journal of magnetic resonance.

[13]  T. Inubushi,et al.  Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. , 1995, Circulation.

[14]  C. V. van Echteld,et al.  Saturation correction in human cardiac 31P MR spectroscopy at 1.5 T , 1994, NMR in biomedicine.

[15]  A. Wechsler,et al.  Derangements in myocardial purine and pyrimidine nucleotide metabolism in patients with coronary artery disease and left ventricular hypertrophy. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Markus von Kienlin,et al.  Spectral localization with optimal pointspread function , 1991 .

[17]  T. Brown,et al.  Quantification of phosphorus metabolites from chemical shift imaging spectra with corrections for point spread effects and B1 inhomogeneity , 1998, Magnetic resonance in medicine.

[18]  P A Bottomley,et al.  Human cardiac high‐energy phosphate metabolite concentrations by 1D‐resolved NMR spectroscopy , 1996, Magnetic resonance in medicine.

[19]  P A Bottomley,et al.  Optimum flip‐angles for exciting NMR with uncertain T1 values , 1994, Magnetic resonance in medicine.

[20]  A Haase,et al.  Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans. , 1998, Journal of magnetic resonance.

[21]  H. Vliegen,et al.  Phosphorus magnetic resonance spectroscopy of the human heart: current status and clinical implications. , 1996, European heart journal.

[22]  P A Bottomley,et al.  MR spectroscopy of the human heart: the status and the challenges. , 1994, Radiology.